genocea provid full year result oper
morn genocea gnca host confer call discuss full year
financi result oper highlight look ahead key event
present initi immunogen data phase i/iia trial guid
late net loss compar net loss
compani end year cash cash equival
recent privat placement expect fund oper
addit manag note appoint new cfo diantha duval
start earli march previous chief account offic vice presid
spin-out bioverativ acquir sanofi
look ahead initi immunogen data manag guid
initi immunogen data part on-going phase i/iia clinic trial
avail late remind part evalu
monotherapi patient evid diseas high risk
relaps part enrol patient first patient dose earli januari part
 trial evalu bristol-my squibb nyse opdivo
nivolumab metastat diseas monotherapi metastat diseas
initi parallel initi data satisfactori
full year result decemb compani cash
cash equival includ gross-proce rais
recent close privat placement financ expens year
compar full-year expens
compar manag note expens remain
rel flat yoy net loss year per share
privat placement first close occur februari
compani issu share pre-fund warrant gross proce
proce first close use clinic trial scale-up name
prepar potenti initi part on-going clinic trial
well ind-en work conting posit top-lin immunogen
data phase i/iia trial genocea option conduct
second close addit proce
immunogen data part phase i/iia studi
file ind
year left
short interest float
includ gross proce privat placement
analyst certif disclosur pleas see page
